Abstract
OBJECTIVE: To evaluate the efficacy of divalproex for the treatment of posttraumatic stress disorder (PTSD) hyperarousal symptom cluster. METHOD: Under double-blind conditions, 85 US military veterans with PTSD were randomized to treatment with divalproex or placebo for 8 weeks. All patients who received at least 1 dose of medication and 1 postbaseline assessment (n = 82) were included in the efficacy population. The primary outcome measure was the hyperarousal subscale of the Clinician-Administered PTSD Scale. RESULT: There were no significant intergroup differences in primary or secondary end points. The final mean (SD) divalproex dose and serum valproic acid level were 2309 ± 507 mg/d and 82 ± 30 mg/L, respectively. CONCLUSIONS: Divalproex monotherapy was not effective in the treatment of chronic PTSD in predominantly older male combat veterans. Further study is needed to determine the efficacy of divalproex in the management of PTSD in women or civilians or in combination with antidepressants.
Original language | English (US) |
---|---|
Pages (from-to) | 84-88 |
Number of pages | 5 |
Journal | Journal of Clinical Psychopharmacology |
Volume | 28 |
Issue number | 1 |
DOIs | |
State | Published - Feb 2008 |
Fingerprint
ASJC Scopus subject areas
- Psychiatry and Mental health
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Divalproex in the treatment of posttraumatic stress disorder : A randomized, double-blind, placebo-controlled trial in a veteran population. / Davis, Lori L.; Davidson, Jonathan R T; Ward, L. Charles; Bartolucci, Al; Bowden, Charles L.; Petty, Frederick.
In: Journal of Clinical Psychopharmacology, Vol. 28, No. 1, 02.2008, p. 84-88.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Divalproex in the treatment of posttraumatic stress disorder
T2 - A randomized, double-blind, placebo-controlled trial in a veteran population
AU - Davis, Lori L.
AU - Davidson, Jonathan R T
AU - Ward, L. Charles
AU - Bartolucci, Al
AU - Bowden, Charles L.
AU - Petty, Frederick
PY - 2008/2
Y1 - 2008/2
N2 - OBJECTIVE: To evaluate the efficacy of divalproex for the treatment of posttraumatic stress disorder (PTSD) hyperarousal symptom cluster. METHOD: Under double-blind conditions, 85 US military veterans with PTSD were randomized to treatment with divalproex or placebo for 8 weeks. All patients who received at least 1 dose of medication and 1 postbaseline assessment (n = 82) were included in the efficacy population. The primary outcome measure was the hyperarousal subscale of the Clinician-Administered PTSD Scale. RESULT: There were no significant intergroup differences in primary or secondary end points. The final mean (SD) divalproex dose and serum valproic acid level were 2309 ± 507 mg/d and 82 ± 30 mg/L, respectively. CONCLUSIONS: Divalproex monotherapy was not effective in the treatment of chronic PTSD in predominantly older male combat veterans. Further study is needed to determine the efficacy of divalproex in the management of PTSD in women or civilians or in combination with antidepressants.
AB - OBJECTIVE: To evaluate the efficacy of divalproex for the treatment of posttraumatic stress disorder (PTSD) hyperarousal symptom cluster. METHOD: Under double-blind conditions, 85 US military veterans with PTSD were randomized to treatment with divalproex or placebo for 8 weeks. All patients who received at least 1 dose of medication and 1 postbaseline assessment (n = 82) were included in the efficacy population. The primary outcome measure was the hyperarousal subscale of the Clinician-Administered PTSD Scale. RESULT: There were no significant intergroup differences in primary or secondary end points. The final mean (SD) divalproex dose and serum valproic acid level were 2309 ± 507 mg/d and 82 ± 30 mg/L, respectively. CONCLUSIONS: Divalproex monotherapy was not effective in the treatment of chronic PTSD in predominantly older male combat veterans. Further study is needed to determine the efficacy of divalproex in the management of PTSD in women or civilians or in combination with antidepressants.
UR - http://www.scopus.com/inward/record.url?scp=38349128467&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38349128467&partnerID=8YFLogxK
U2 - 10.1097/JCP.0b013e318160f83b
DO - 10.1097/JCP.0b013e318160f83b
M3 - Article
C2 - 18204347
AN - SCOPUS:38349128467
VL - 28
SP - 84
EP - 88
JO - Journal of Clinical Psychopharmacology
JF - Journal of Clinical Psychopharmacology
SN - 0271-0749
IS - 1
ER -